The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Overexpression of phosphatidylinositol phosphate 5-kinase alpha (PIP5KIalpha), which synthesizes PIP2, suppresses apoptosis, whereas a kinase-deficient mutant does not. Protection by the wild-type PIP5KIalpha isaccompanied by decreases in the generation of activated caspases and of caspase 3-cleaved PARP. Protection is not mediated through PIP3 or Akt activation. An anti-apoptotic role for PIP(2) is substantiated by the finding that PIP5KIalpha is cleaved by caspase 3 during apoptosis, and cleavage inactivates PIP5KIalpha in vitro. Mutation of the P(4) position (D279A) of the PIP5KIalpha caspase 3 cleavage consensus prevents cleavage in vitro, and during apoptosis in vivo. Significantly, the caspase 3-resistant PIP5KIalpha mutant is more effective in suppressing apoptosis than the wild-type kinase. PIP2 is a direct regulator of apical and effector caspases in the death receptor and mitochondrial pathways, and PIP5KIalpha inactivation contributes to the progression of apoptosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: 68 kDa type I phosphatidylinositol 4-phosphate 5-kinase; 68 kDa type I phosphatidylinositol 4-phosphate 5-kinase alpha; 68 kDa type I phosphatidylinositol-4-phosphate 5-kinase alpha; Phosphatidylinositol 4-phosphate 5-kinase type I alpha; Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha; phosphatidylinositol-4-phosphate 5-kinase; phosphatidylinositol-4-phosphate 5-kinase type-1 alpha; phosphatidylinositol-4-phosphate 5-kinase, type 1 beta; phosphatidylinositol-4-phosphate 5-kinase, type I, alpha; PI51A; PIP5K1-alpha; PIP5KIalpha; ptdIns(4)P-5-kinase 1 alpha
Gene Aliases: PIP5K1A; Pip5k1b
UniProt ID: (Human) Q99755